Jiayang Liu, Tongyang Xu, Danjie Pan, Jiajun Fan, Yuan Fu, Xiting Huang, Weili Zhao, Xiaochun Dong, Shaohui Zhang, Kudelaidi Kuerban, Xuan Huang, Songna Wang, Huaning Chen, Yunpeng He, Yi Zhun Zhu, Congjun Wang, Li Ye
Collagen is abundant but exposed in tumor due to the abnormal tumor blood vessels, thus is considered as a tumor-specific target. The A3 domain of von Willebrand factor (vWF A3) is a kind of collagen-binding domain (CBD) which could bind collagen specifically. Previously we reported a chemosynthetic CBD-SIRPαFc conjugate, which could block CD47 and derived tumor-targeting ability by CBD. CBD-SIRPαFc conjugate represented improved anti-tumor efficacy with increased MHC II+ M1 macrophages, but the uncertain coupling ratio remained a problem...
September 16, 2023: International Immunopharmacology